Down Syndrome Health and Developmental Outcomes

Down syndrome is a genetic condition arising from the presence of an extra copy of chromosome 21. This chromosomal imbalance results in a characteristic constellation of physical, neurological and immunological features. Congenital heart disease, including atrioventricular septal defects and pulmonary hypertension, affects around half of all individuals, driving early morbidity and requiring specialised care. Cognitive impairment ranges from mild to moderate, with distinct profiles of learning, memory and language. Adults with Down syndrome face an elevated risk of early-onset Alzheimer’s disease and associated dementia, along with variable profiles of epilepsy, thyroid dysfunction, autoimmune disorders and haematological malignancies. Advances in life expectancy now extend into the seventh decade, shifting focus to age-related comorbidities and quality of life. Epidemiological studies reveal divergent trajectories of disease incidence and clustering of syndromic conditions across the lifespan, emphasising the need for tailored screening, prevention and therapeutic strategies grounded in a holistic understanding of physical and developmental health.

Research from Nature Portfolio

Recent studies have delineated mechanistic links between gene dosage on chromosome 21 and systemic phenotypes. Genome editing in a mouse model has shown that normalising the copy number of the interferon receptor cluster mitigates chronic inflammation, prevents cardiac malformations and improves cognitive and craniofacial outcomes, suggesting that overactive interferon signalling is a key driver of multiple hallmarks of the syndrome. Complementing this, large-scale proteomic analyses of blood samples from individuals with Down syndrome reveal a pattern of chronic autoinflammation, marked by elevated pro-inflammatory cytokines, complement consumption and dysregulated immune mediators. These findings frame Down syndrome in part as an interferonopathy, pointing to immune-modulatory therapies as a promising avenue to ameliorate diverse clinical manifestations.

Down Syndrome Health and Developmental Outcomes publication trend

The graph below shows the total number of articles in down syndrome health and developmental outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Trisomy 21: The presence of three copies of chromosome 21 instead of two, causing Down syndrome.

Interferonopathy: A disorder characterised by excessive activation of interferon signalling pathways leading to chronic inflammation.

Proteomics: The large-scale study of proteins, their structures and functions within a biological sample.

Morbidity: The incidence of disease or medical conditions in a population over time.

Congenital heart disease: Structural abnormalities of the heart or great vessels present at birth.

Dementia: A collective term for progressive decline in memory and cognitive function impairing daily life.

Cytokine: A signalling protein released by immune cells that modulates inflammation and immune responses.

References

1. Cardiovascular Complications of Down Syndrome: Scoping Review and Expert Consensus. Circulation (2023).
2. Triplication of the interferon receptor locus contributes to hallmarks of Down syndrome in a mouse model. Nature Genetics (2023).
3. Multiple morbidity across the lifespan in people with Down syndrome or intellectual disabilities: a population-based cohort study using electronic health records. The Lancet Public Health (2023).
4. Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation. Scientific Reports (2017).
5. Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years. JAMA Neurology (2019).